Sibiman BioCBM-ALAM.1 Allogeneic Human-induced Fat-Charged Progenitor Cell Injection obtained ByCDE
-
Last Update: 2020-06-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
November 7, on the CDE official website, The CBM-ALAM.1 transhetatoi-intransgenic supermyte progenitor progenitor injection applied by Sibiman Biological Group (NASDAQ: CBMG) was accepted under the acceptance number CXSL1800109the declaredofdrugs (type 1 new drugtherapeutic biologicsit is understood that the application for stem cell technology AlloJoin ® treatment comes from clinical research data on the treatment of knee osteoarthritis from Sibiman's mature cell technology platform and the inter-containing fat source ReJoin ®in addition to the safety and efficacy of the treatment of knee osteoarthritis in the previous ReJoin ® clinicaltrial
s (in which the safety and efficacy of the treatment of intrabody fat protoplasm progenitor cells have been demonstrated), the safety of heterogeneous progenitor progenitor cells has also been identified in clinical trials of AlloJoin ®also, animal experiments conducted by Sibiman Bio provide preliminary evidence of the effects of heterogeneous fat-filled progenitor cells in the treatment of knee osteoarthritis
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
